Clinical Updates on Tuberculosis and STDs

Day 1: September 30th, 2019

• Registration/check-in: 7:30am - 8:30am
• Start time: 8:30am - 4:30pm

Day 2: October 1st, 2019

• Registration/check-in: 7:30am-8:00am
• Start time: 8:00am - 4:30pm

Application Deadline: September 13, 2019

Enrollment is limited and pre-registration is required. To apply, please click the Apply button at the bottom of this screen. Note that you will be asked to log in or create an account if you haven't already done so. Applicants will be informed of their registration status within a few days of the application deadline. Directions and other information will be included with acceptance emails. 

Cost: There is no fee for this training. 

Credit: This training is approved for up to 12 continuing education hours (see below). Certificates will be available approximately 12 weeks after the training.

Target Audience: This training is intended for clinicians in Nevada, as well as Utah, Arizona, and Southern California. 

Topics Will Include:

• TB and STD epidemiology in Nevada
• Interpretation and use of IGRAs for diagnostic testing
• Treatment options and pre-treatment counseling for latent TB infection
• Diagnosis, treatment and management of active TB disease
• Diagnostic and treatment updates for gonorrhea, chlamydia and syphilis
• HIV updates on PrEP and rapid testing

Learning Objectives (partial list): 

Upon completion of this training, participants will be able to:

• identify key populations in Nevada at risk for tuberculosis infection and disease based on current epidemiological data to inform the prioritization of populations for testing and treatment
• identify at least 3 groups who are at risk for tuberculosis and should undergo screening to prevent tuberculosis disease and transmission
• discuss pros and cons for the tuberculosis skin tests (TSTs) versus interferon-gamma release assays (IGRAs) and how they may apply to different risk groups to improve application in clinical practice
• list four recommended treatment options for latent tuberculosis infection (LTBI) and describe the advantages versus disadvantages to each to inform clinical judgment in choosing the optimum regimen for patient care
• summarize issues related to the development of antibiotic resistance in Neisseria gonorrhoeae, to ensure appropriate treatment and follow-up testing
• summarize current screening recommendations for chlamydia and gonorrhea to ensure infections are diagnosed and treated
• describe current syphilis epidemiology within the United States and clinical manifestations, screening recommendations, diagnostic approach, staging, and management of syphilis, to better improve screening and treatment of syphilis cases
• summarize current recommendations for screening and diagnosis of HIV, and discuss the importance of initiating HIV treatment, to reduce infectiousness and decrease STD/HIV transmission
• discuss current data on PrEP effectiveness, and monitoring for HIV infection, STIs, and renal function, to better utilize HIV prevention methods and manage patient preventative care
• understand current range of PrEP delivery models, to better incorporate PrEP mechanisms into clinical care
• name at least 1 resource for providers seeking consultation about PrEP, to assist with implementing PrEP in a clinic setting

 Faculty (partial list):

    Joe Iser, MD, DrPH, MSc
    Chief Health Officer
    Southern Nevada Health District

    Susan McElhany, DMD
    TB Program Manager
    Nevada Department of Health and Human Services

    Vit Kraushaar, MD, MPH
    Medical Investigator
    Office of Epidemiology and Disease Surveillance
    Southern Nevada Health District

    Elizabeth Kessler, MPH
    STD Program Manager
    Nevada Division of Public and Behavioral Health

    John Wilson, MD, FIDSA
    Associate Professor of Medicine
    Mayo Clinic, Division of Infectious Diseases

    Jerry Cade, MD, MBA
    Medical Director, Viral Specialty Treatment Service
    University Medical Center
    Las Vegas, NV

.

The Curry International Tuberculosis Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This training is approved for up to 12 continuing education hours.

The Curry International Tuberculosis Center designates this educational activity for a maximum of 12 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The Curry International Tuberculosis Center is approved as a provider of continuing education by the California State Board of Registered Nurses, Provider Number CEP 12308. This training is approved for up to 12 continuing education hours. Board requirements prevent us from offering CE credit to people who arrive more than 15 minutes after the start of the training, or leave the training early. Therefore, partial credit will not be awarded.

.

The Curry International Tuberculosis Center is designated as a Tuberculosis Center of Excellence for Training, Education, and Medical Consultation (TB COE) via a funded cooperative agreement with the Centers for Disease Control and Prevention. The Curry International Tuberculosis Center prioritizes learners from the western region of the United States which consists of seventeen jurisdictions: Alaska, Arizona, California (including Los Angeles, San Diego, and San Francisco), Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, Wyoming, and the U.S. Pacific Island Territories.